Trade Fresenius Medical Care AG & Co KGaA - FME CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.11
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.018016 %(-€3.60)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.01802%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.004207 %(-€0.84)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.00421%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: Germany
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.018016 %
  (-€3.60)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.004207 %
  (-€0.84)

Key Stats

• Prev. Close: 39.65
• Open: 40.1
• 1-Year Change: -8.05%
• Day's Range: 40.1 - 40.64

Trade Fresenius Medical Care AG & Co KGaA - FME

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Fresenius Medical Care AG & Co. KGaA revenues decreased 1% to EUR17.62B. Net income decreased 17% to EUR969M. Revenues reflect Health Care Services decrease of 2% to EUR13.88B, Health Care Products remaining flat at EUR3.74B. Net income also reflects Income from equity method investees decrease of 3% to EUR92M (income). Dividend per share increased from EUR1.34 to EUR1.35.

Equity composition

1/2006, 1-for-1 Complex capital change(Factor: 1). 3/2006, Company name changed from Fresenius Medical Care AG. 06/2007, 3-for-1 stock split.